WVE · NASDAQ
Wave Life Sciences Ltd.
$3.44 +0.22 (+6.83%)
Company overview
Wave Life Sciences Ltd. is a clinical-stage genetic medicine company that designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug development platform. The company is developing oligonucleotides that target ribonucleic acid to reduce the expression of disease-promoting proteins, restore the production of functional proteins, or modulate protein expression. Its pipeline includes WVE-004 for amyotrophic lateral sclerosis and frontotemporal dementia, WVE-003 for Huntington's disease, WVE-N531 for Duchenne muscular dystrophy, and ATXN3 for spinocerebellar ataxia 3, along with multiple preclinical programs for central nervous system disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $678M
- Employees
- 287
- Headquarters
- Singapore
- Website
- wavelifesciences.com
- CEO
- Paul Bolno
- Listed
- November 11, 2015
- P/E
- -3.25
- Dividend yield
- 0.00%
Company financials
- Revenue
- $71.8M
- Gross profit
- $67.3M
- Operating income
- -$197M
- EBITDA
- -$182M
- Net income
- -$184M
- EPS
- -$1.06
- Total assets
- $584M
- Total debt
- $15.7M
- Gross margin
- 93.79%
- Net margin
- -255.70%
- Earnings yield
- -30.81%
No annual segmentation.
No geographic segmentation.
WVE
1D
NASDAQ
O3.17H3.24L3.13C3.21+0.03 (+0.94%)Vol3.22M